Please login to the form below
Bioequivalence study triggers milestone payment for Eurand
Eurand completes a bioequivalence study with GlaxoSmithKline regarding an undisclosed GSK compound
Eurand, an Italian/ US-based specialty pharmaceutical company, has successfully completed a bioequivalence study with GlaxoSmithKline (GSK), regarding an undisclosed GSK compound.
UK-headquartered GSK will make a payment of USD 1.5m to Eurand in recognition of the milestone.
The new formulation, which uses Eurand's Microcaps and AdvaTab technologies, is designed to dissolve quickly in the mouth to reduce the bitter taste of some medications. Eurand could potentially receive milestone payments from GSK totalling up to USD 42m for the development of the product. GSK expects to file an NDA in the near future.
Under the agreement, Eurand will manufacture the product for GSK and receive royalty revenues when the product receives NDA approval from the FDA.
Gearoid Faherty, CEO of Eurand, said: "We are delighted with the results of the bio-study and are looking forward to GSK submitting their NDA."
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
-
Senior External Communications Lead
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
-
Account Manager
-
£Competitive Salary
-
Account Director
-
£Competitive Salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
- UK, China prep trials of coronavirus vaccine candidates
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- China backs use of Roche’s Actemra for coronavirus
- Sanofi, Regeneron launch trials of arthritis drug Kevzara for COVID-19
- Novartis donates malaria drug for COVID-19 clinical trials
- Moderna and GSK advance coronavirus vaccine candidates
- Incyte and Novartis join coronavirus efforts with phase 3 study
- Moderna chairman says COVID-19 vaccine could begin phase 2 trials in spring
- Merck’s Keytruda beats chemo in first-line colorectal cancer
- “Fake News” and Credibility in Medical Publishing
- How Much Does Each Advisor “Insight” Actually Cost?
- It's not just our logo that's green
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
Latest intelligence
- “Fake News” and Credibility in Medical Publishing
- Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
- Delivering true value: what does it mean for KAM in cancer care?
- Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
- Pharma funding and M&A in 2020
- Why pharma M&A has continually bucked the trend...
Quick links
Infographics
